EMA begins analyzing Bavarian Nordic's vaccine against monkeypox

Prior to deciding on a shared European vaccine supply purchase, the European Medicines Agency has begun analyzing the Danish firm’s smallpox vaccine against monkeypox.
Photo: Lukas Barth/Reuters/Ritzau Scanpix
Photo: Lukas Barth/Reuters/Ritzau Scanpix
by christopher due karlsson, translated by daniel pedersen

The European Medicines Agency (EMA) has begun a risk/benefit analysis of using Danish biotech firm Bavarian Nordic’s smallpox vaccine against monkeypox, according to a press release from Sweden’s prime minister’s office.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading